Table 4.

Baseline plasma selenium and the effect of treatment on prostate cancer diagnosis among those evaluable for study outcome

Known endpointsCancer in patients with known endpointRR of prostate cancer in the selenium arm compared with placebo arm
QuartileSelenium concentration, ng/mLSelenium, NPlacebo, NSelenium, N (%)Placebo, N (%)RR (95% CI)
1<10631319 (29.0)11 (35.48)0.82 (0.40–1.69)
2106–132303112 (40.0)9 (29.3)1.38 (0.68–2.78)
3132–162323614 (43.8)16 (44.4)0.98 (0.58–1.68)
4>162323210 (31.25)11 (34.4)0.91 (0.45–1.84)
Missing baseline seleniuma10432
Total12513045 (36.0)47 (36.2)0.97 (0.68–1.39)
  • aNot included in totals.